Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 10/20 | 0.94 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.85 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.85 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.85 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.76 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.76 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13791646 | 1.00 | NR1I2 (0.94) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL12034527 | 0.97 | NR1I2 (1.00) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL3929563 | 0.96 | NR1I2 (0.93) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL13791299 | 0.95 | NR1I2 (0.92) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL3931034 | 0.93 | NR1I2 (0.93) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL14070300 | 0.93 | NR1I2 (0.88) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL13791586 | 0.93 | NR1I2 (0.93) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL13869361 | 0.93 | NR1I2 (0.88) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL13869364 | 0.93 | NR1I2 (0.88) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL13869366 | 0.93 | NR1I2 (0.88) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2118109-B1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2014-11-26 | — | — | EP | disclosed |
| WO-2008112473-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-09-18 | — | — | WO | disclosed |
| US-20080227769-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2008-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227769-A1 | Compounds for the Treatment of Hepatitis C | SLC10A1, HAVCR2, NR1H4 | NR1I2 175/4885KCNH2 3045/4885CYP3A4 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.